Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $395000.0.

  • Keros Therapeutics' Depreciation & Amortization (CF) rose 2579.62% to $395000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 2596.15%. This contributed to the annual value of $1.2 million for FY2024, which is 5079.75% up from last year.
  • Per Keros Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $395000.0 for Q3 2025, which was up 2579.62% from $370000.0 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Depreciation & Amortization (CF) registered a high of $395000.0 during Q3 2025, and its lowest value of $80000.0 during Q1 2021.
  • For the 5-year period, Keros Therapeutics' Depreciation & Amortization (CF) averaged around $221315.8, with its median value being $210000.0 (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 23846.15% in 2022, then plummeted by 3798.7% in 2023.
  • Quarter analysis of 5 years shows Keros Therapeutics' Depreciation & Amortization (CF) stood at $104000.0 in 2021, then grew by 22.12% to $127000.0 in 2022, then skyrocketed by 94.49% to $247000.0 in 2023, then skyrocketed by 34.41% to $332000.0 in 2024, then grew by 18.98% to $395000.0 in 2025.
  • Its last three reported values are $395000.0 in Q3 2025, $370000.0 for Q2 2025, and $344000.0 during Q1 2025.